Adverse reactions occurring in ≥2% of DUPIXENT patients through Week 24 and greater than placebo (pooled safety across PRIME and PRIME2)1
| ADVERSE REACTION | DUPIXENT 300 mg Q2W (n=152) % |
PLACEBO (n=157) % |
|---|---|---|
| Nasopharyngitisa | 5 | 2 |
| Conjunctivitisb | 4 | 1 |
| Herpes infectionc | 3 | 0 |
| Dizzinessd | 3 | 1 |
| Myalgiae | 3 | 1 |
| Diarrhea | 3 | 1 |
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
aNasopharyngitis includes pharyngitis.
bConjunctivitis includes conjunctivitis and allergic conjunctivitis.
cHerpes infection includes oral herpes, genital herpes simplex, herpes zoster, and ophthalmic herpes zoster.
dDizziness includes dizziness postural, vertigo, and vertigo positional.
eMyalgia includes musculoskeletal pain and musculoskeletal chest pain.
Attributes and considerations
NOT AN
IMMUNOSUPPRESSANT
OR A STEROID1
NO KNOWN DRUG-TO-DRUG
INTERACTIONS1
Not metabolized through the liver or excreted through the kidneys
NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING
according to the Prescribing Information1
NO BOXED WARNING1
Please see additional Warnings and Precautions in the
Prescribing Information and Important Safety Information below.
SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
Watch healthcare providers discuss
treatment with DUPIXENT
Q2W, once every 2 weeks.